Overview

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Status:
Recruiting
Trial end date:
2021-10-13
Target enrollment:
Participant gender:
Summary
The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Zealand Pharma